FGFR2 antibody, FGFR2 Antibody, Rabbit Polyclonal Antibody

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

FGFR2 Antibody, Rabbit Polyclonal Antibody

Catalog Number: 18-272-195176

Buy FGFR2 antibody -

Volume:

Related Product Names:

- FGFR2 antibody; FGFR2; 2263; FGFR2; 101200; P21802; BEK; BFR-1; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25;; FGFR2
- Rabbit polyclonal to FGFR2; 2263; FGFR2; 101200; P21802; BEK; BFR-1; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25;; Fibroblast growth factor receptor 2

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: FGFR2	Gene Name Synonym: 2263; FGFR2; 101200; P21802; BEK; BFR-1; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25;
Gi #: N/A	NCBI Acc #: NP_000132.2	Swiss Prot Acc #: P21802
Length (aa): N/A	Mol. Weight (Da): 92025	Chrom Location: N/A

Isotype: IgG

Immunogen: Synthetic peptide: KLPQYPHIGSVKT conjugated to KLH by a Glutaraldehyde linker, corresponding to amino acids 809-821 of the cytoplasmic region of Human FGFR2.

Antigen Species: Human

Specificity: FGFR2, Cytoplasmic reacts specifically with FGFR2 using immunoblotting and immunoprecipitation (doublet at 115-125kD) using whole cell lysates of transfected 293T cells, a human, embryonic kidney cell line, expressing recombinant human FGFR2. No reaction with human FGFR1 and FGFR3 is detected.

Target: FGFR2

Localization: Cytoplasmic

Concentration: 1 mg/ml

Storage Buffer: 0.01M Phosphate-buffered saline, pH7.4, containing 1% bovine serum albumin and 15mM sodium azide

Application Note: IHC: Use at an assay dependent dilution, this concentration is determined by indirect immunoperoxidase staining of trypsin or protease-digested, formalin-fixed, paraffin-embedded human and animal tissue sections. IP: Use at a dilution of 1:2,000. This concentration is determined by immunoprecipitation using a whole lysate of transfected cells expressing recombinant human FGFR2. WB: Use at a dilution of 1:2,000. This concentration is determined by immunoblotting using a whole extract of transfected cells expressing recombinant human FGFR2. Predicted molecular weight: 110 kDa. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user.

Cellular Localization: Cytoplasmic

Source/Host: Rabbit

Purity/Purification: Immunogen affinity purified

Clonality: Polyclonal

Crossreactivity: Cross-reacts with Human. Expected to cross-react with Mouse (92% identity with immunogen) and Rat (92% identity with immunogen) due to sequence homology. Not yet tested in other species.

Format: Liquid

Storage: Keep as concentrated solution. Store at 4C short term. For extended storage aliquot and store at -20C or below. Avoid freeze-thaw cycles.

Shipping: Products may be shipped on ice pack or dry ice.

APPLICATIONS for FGFR2 ANTIBODY:

IHC, IP, WB: Tested

TESTING: (secondary reagents and protocols )

Not Available

FGFR2 ANTIBODY TARGET DESCRIPTION:

Synonym Names for FGFR2 antibody: FGFR2; 2263; FGFR2; 101200; P21802; BEK; BFR-1; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25;; Rabbit polyclonal to FGFR2; 2263; FGFR2; 101200; P21802; BEK; BFR-1; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25;; Fibroblast growth factor receptor 2

Fibroblast growth factors (FGFs) are members of a large family of structurally related heparin binding polypeptides (17-38kD) that are potent physiological regulators of growth and differentiation for a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They have also been implicated in pathological conditions such as tumorigenesis and metastasis. The FGF family consists of at least seventeen members designated FGF1 through FGF17. To date, four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg, cek-1], FGFR2 [bek, cek-3], FGFR3 [cek-2] and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported. Soluble, secreted8 or possibly cleaved9 forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110-150 kD proteins that are constructed of an extracellular ligand binding region with either two or typically three immunoglobulin (Ig)-like domains and an eight amino acid ëacidic boxí, a transmembrane region and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of all FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind several of the FGFs with a similar affinity. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGFs binding to cellular FGFRs depends on, or is markedly facilitated by the low-affinity interaction of FGFs with the polysaccharide component of cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR- 2 is highly expressed in developing human tissues including the brain (preferentially in glial cells), choroid plexus, skin, lung, kidney and bone. It is widely expressed in many adult human and animal tissues. It may be found in several anchorage-dependent cells, such as normal and malignant breast cancer cells. Crouzon as well as other craniosynostosis syndromes (e.g. Pfeifferís, Apertís, Jackson-Weissí), disorders of human skeletal development, have been shown to be the result of mutations in the extracellular domain of FGFR2.

Function: Receptor for acidic and basic fibroblast growth factors.

Catalytic Activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.

Subcellular Location: Cell membrane; Single-pass type I membrane protein.

Subcellular Location: Isoform 14: Secreted.

Subcellular Location: Isoform 19: Secreted.

Disease: Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:123500]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.

Disease: Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:123150]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.

Disease: Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:101200]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.

Disease: Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).

Disease: Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:123790]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.

Disease: Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:609579]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.

Disease: Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.

Disease: Defects in FGFR2 are the cause of Antley-Bixler syndrome (ABS) [MIM:207410]. ABS is a multiple congenital anomaly syndrome characterized by craniosynostosis, radiohumeral synostosis, midface hypoplasia, malformed ears, arachnodactyly and multiple joint contractures. ABS is a heterogeneous disorder and occurs with and without abnormal genitalia in both sexes.

Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.

Similarity: Contains 3 Ig-like C2-type (immunoglobulin-like) domains.

Similarity: Contains 1 protein kinase domain.

FGFR2 reacts with cross-reacts with human. expected to cross-react with mouse (92% identity with immunogen) and rat (92% identity with immunogen) due to sequence homology. not yet tested in other species..

OMIM: 101200; phenotype. [NCBI / EBI]
101600; phenotype. [NCBI / EBI]
123150; phenotype. [NCBI / EBI]
123500; phenotype. [NCBI / EBI]
123790; phenotype. [NCBI / EBI]
149730; phenotype. [NCBI / EBI]
176943; gene. [NCBI / EBI]
207410; phenotype. [NCBI / EBI]
609579; phenotype. [NCBI / EBI]

Products similar to FGFR2 antibody:

IgG

p70 S6 Kinase (Ab-411), IgG

p70 S6 Kinase (Phospho-Ser424), IgG

S6K, IgG

p70S6K, IgG

p70S6K / RPS6KB1, IgG

Peptide

p70 S6 Kinase Phospho-Ser411) Antibody Blocking Peptide, Peptide

p70 S6 Kinase (Phospho-Thr421) Antibody Blocking Peptide, Peptide

p70 S6 Kinase (Phospho-Ser424) Antibody Blocking Peptide, Peptide

PRODUCT INTERACTIONS:

FGFR2 interacts with Acidic Fibroblast Growth Factor, Protein (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF ACIDIC, Protein (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF ACIDIC, IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with Rabbit anti FGF acidic, IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with Human FGF-acidic,, Protein (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF acidic (Biotin), IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF10, IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF BASIC, Protein (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF BASIC, IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF basic [AS25] (Biotin), IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF basic [F-343], IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF basic [F-74], IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF basic [F-474], IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF basic [MC-GF1], IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with bFGF, IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with Human FGF-basic,, Protein (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF2 [FB-8], IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF basic, IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF basic [AS24], IgG (GenWay Catalog #: 18-272-195176).

FGFR2 interacts with FGF BASIC, IgG (GenWay Catalog #: 18-272-195176).

SUGGESTED ANITBODY REAGENTS - GenWay has an extensive selection of reagents useful for antibody applications. Find blocking buffers, stop reagents, chemiluminescent substrates, diluents, Immunohistochemistry reagents & more.

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: FGFR2 antibody is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of FGFR2 antibody vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about FGFR2 antibody, all related information, articles, resources about FGFR2 antibody are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

Thank you for visiting GenWay Biotech's Datasheet. GenWay is the world's leader in chicken, IgY antibody production, producing over 900 quality polyclonal IgY antibodies to date. From our unique recombinant protein production, utilizing a variety of protein expression systems, GenWay's polyclonal IgY antibodies incorporate more epitopes, increasing the success rate for ELISA, western blot, immunohistochemistry (IHC), immunocytochemistry (ICC), and many more immunoassays.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved